Publikationen, an denen er mitarbeitet Juan Berenguer Berenguer (86)

2023

  1. Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age

    HIV Medicine, Vol. 24, Núm. 1, pp. 27-36

  2. Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2

    Viruses, Vol. 15, Núm. 7

  3. Recently acquired hepatitis C: Epidemiological characteristics and treatment response in a large cohort of MSM living with HIV in Madrid

    Enfermedades Infecciosas y Microbiologia Clinica

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

  3. Manejo de la infección por SARS-CoV-2 en urgencias

    Revista Española de Urgencias y Emergencias, Vol. 1, Núm. 1, pp. 38-43

  4. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

  5. Progress in the quality of care for newly diagnosed people with HIV in Spain (2004–2019)

    Antiviral Therapy, Vol. 27, Núm. 4

  6. SARS-COV-2 Infection in People Living with HIV: Experience from a Tertiary Hospital in Madrid

    AIDS Research and Human Retroviruses, Vol. 38, Núm. 5, pp. 394-398

  7. Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort

    Infectious Diseases and Therapy, Vol. 11, Núm. 3, pp. 1177-1192

  8. Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19

    Journal of Infection

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: The COVID-19 SEIMC score

    Thorax, Vol. 76, Núm. 9, pp. 920-929

  3. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

    Journal of Biomedical Science, Vol. 28, Núm. 1

  4. Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort

    Clinical Microbiology and Infection, Vol. 27, Núm. 11, pp. 1678-1684

  5. Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV

    PloS one, Vol. 16, Núm. 4, pp. e0249515

  6. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

    Clinical Microbiology and Infection, Vol. 27, Núm. 2, pp. 244-252

  7. eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort

    HIV Research and Clinical Practice, Vol. 22, Núm. 3, pp. 78-85

2020

  1. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0

    HIV Medicine, Vol. 21, Núm. 10, pp. 617-624

  2. Autologous stem cell transplantation for lymphoma in HIV+ patients: higher rate of infections compared with non-HIV lymphoma

    Bone Marrow Transplantation, Vol. 55, Núm. 9, pp. 1716-1725